The quest to overcome resistance to EGFR-targeted therapies in cancer

Aurora Kinase Inhibition Overcomes Cetuximab Resistance in Squamous Cell Cancer of the Head and Neck

(2015) Alexander Hoellein et al.   Oncotarget

Primary resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in patients with non-small-cell lung cancer harboring TKI-sensitive EGFR mutations: an exploratory study

(2013) J. K. Lee et al.   ANNALS OF ONCOLOGY

Acquired Resistance to EGFR Inhibitors Is Associated with a Manifestation of Stem Cell-like Properties in Cancer Cells

(2013) K. Shien et al.   CANCER RESEARCH

DNA-Mutation Inventory to Refine and Enhance Cancer Treatment (DIRECT): A Catalog of Clinically Relevant Cancer Mutations to Enable Genome-Directed Anticancer Therapy

(2013) P. Yeh et al.   CLINICAL CANCER RESEARCH

Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung Cancers

(2013) H. A. Yu et al.   CLINICAL CANCER RESEARCH

A novel serum protein signature associated with resistance to epidermal growth factor receptor tyrosine kinase inhibitors in head and neck squamous cell carcinoma

(2013) Carol Box et al.   EUROPEAN JOURNAL OF CANCER

Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor–Resistant Disease

(2013) Kadoaki Ohashi et al.   JOURNAL OF CLINICAL ONCOLOGY

Natural History and Molecular Characteristics of Lung Cancers Harboring EGFR Exon 20 Insertions

(2013) Geoffrey R. Oxnard et al.   Journal of Thoracic Oncology

High-dose, pulsatile erlotinib in two NSCLC patients with leptomeningeal metastases—One with a remarkable thoracic response as well

(2013) J.L. Kuiper et al.   LUNG CANCER

Activation of the FGF2-FGFR1 Autocrine Pathway: A Novel Mechanism of Acquired Resistance to Gefitinib in NSCLC

(2013) Hideki Terai et al.   MOLECULAR CANCER RESEARCH

EGFR Exon 20 Insertion Mutations in Lung Adenocarcinomas: Prevalence, Molecular Heterogeneity, and Clinicopathologic Characteristics

(2013) M. E. Arcila et al.   MOLECULAR CANCER THERAPEUTICS

Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance

(2013) Meghna Das Thakur et al.   NATURE

Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA

(2013) Muhammed Murtaza et al.   NATURE

The Role of MET Receptor Tyrosine Kinase in Non-Small Cell Lung Cancer and Clinical Development of Targeted Anti-MET Agents

(2013) K. W. Robinson et al.   ONCOLOGIST

Skin Rash could Predict the Response to EGFR Tyrosine Kinase Inhibitor and the Prognosis for Patients with Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis

(2013) Hong-bing Liu et al.   PLoS One

PUMA and BIM Are Required for Oncogene Inactivation-Induced Apoptosis

(2013) G. R. Bean et al.   Science Signaling

Maximizing the Benefits of Off-Target Kinase Inhibitor Activity

(2013) Monica Red Brewer et al.   Cancer Discovery

A mechanism of resistance to gefitinib mediated by cellular reprogramming and the acquisition of an FGF2-FGFR1 autocrine growth loop

(2013) K E Ware et al.   Oncogenesis

A phase II trial of dacomitinib, an oral pan-human EGF receptor (HER) inhibitor, as first-line treatment in recurrent and/or metastatic squamous-cell carcinoma of the head and neck

(2012) A. R. Abdul Razak et al.   ANNALS OF ONCOLOGY

NKX2-1/TITF1/TTF-1-Induced ROR1 Is Required to Sustain EGFR Survival Signaling in Lung Adenocarcinoma

(2012) Tomoya Yamaguchi et al.   CANCER CELL

EGF Receptor Signaling Is Essential for K-Ras Oncogene-Driven Pancreatic Ductal Adenocarcinoma

(2012) Carolina Navas et al.   CANCER CELL

EGF Receptor Is Required for KRAS-Induced Pancreatic Tumorigenesis

(2012) Christine M. Ardito et al.   CANCER CELL

Resistance to Irreversible EGF Receptor Tyrosine Kinase Inhibitors through a Multistep Mechanism Involving the IGF1R Pathway

(2012) A. B. Cortot et al.   CANCER RESEARCH

JAK2-related pathway induces acquired erlotinib resistance in lung cancer cells harboring an epidermal growth factor receptor-activating mutation

(2012) Daijiro Harada et al.   CANCER SCIENCE

MED12 Controls the Response to Multiple Cancer Drugs through Regulation of TGF-β Receptor Signaling

(2012) Sidong Huang et al.   CELL

Methylation of death-associated protein kinase is associated with cetuximab and erlotinib resistance

(2012) Takenori Ogawa et al.   CELL CYCLE

Clinical Outcomes in Non-Small Cell Lung Cancers Harboring Different Exon 19 Deletions in EGFR

(2012) K.-P. Chung et al.   CLINICAL CANCER RESEARCH

Drug Absorption Interactions Between Oral Targeted Anticancer Agents and PPIs: Is pH-Dependent Solubility the Achilles Heel of Targeted Therapy?

(2012) N R Budha et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Second-generation irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs): A better mousetrap? A review of the clinical evidence

(2012) Sai-Hong Ignatius Ou   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Plasma exposure of imatinib and its correlation with clinical response in the Tyrosine Kinase Inhibitor Optimization and Selectivity Trial

(2012) F. Guilhot et al.   HAEMATOLOGICA

Dual Targeting of the Epidermal Growth Factor Receptor Using the Combination of Cetuximab and Erlotinib: Preclinical Evaluation and Results of the Phase II DUX Study in Chemotherapy-Refractory, Advanced Colorectal Cancer

(2012) Andrew J. Weickhardt et al.   JOURNAL OF CLINICAL ONCOLOGY

Randomized Phase II Trial of Erlotinib Alone or With Carboplatin and Paclitaxel in Patients Who Were Never or Light Former Smokers With Advanced Lung Adenocarcinoma: CALGB 30406 Trial

(2012) Pasi A. Jänne et al.   JOURNAL OF CLINICAL ONCOLOGY

Sunitinib Plus Erlotinib Versus Placebo Plus Erlotinib in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer: A Phase III Trial

(2012) Giorgio V. Scagliotti et al.   JOURNAL OF CLINICAL ONCOLOGY

Effects of Pharmacokinetic Processes and Varied Dosing Schedules on the Dynamics of Acquired Resistance to Erlotinib in EGFR-Mutant Lung Cancer

(2012) Jasmine Foo et al.   Journal of Thoracic Oncology

Screening for Germline EGFR T790M Mutations Through Lung Cancer Genotyping

(2012) Geoffrey R. Oxnard et al.   Journal of Thoracic Oncology

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

(2012) Rafael Rosell et al.   LANCET ONCOLOGY

Relationship between skin rash and outcome in non-small-cell lung cancer patients treated with anti-EGFR tyrosine kinase inhibitors: A literature-based meta-analysis of 24 trials

(2012) Fausto Petrelli et al.   LUNG CANCER

Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR

(2012) Anirudh Prahallad et al.   NATURE

Mutations in UVSSA cause UV-sensitive syndrome and destabilize ERCC6 in transcription-coupled DNA repair

(2012) Xue Zhang et al.   NATURE GENETICS

Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer

(2012) Clara Montagut et al.   NATURE MEDICINE

A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer

(2012) King Pan Ng et al.   NATURE MEDICINE

Survival in BRAF V600–Mutant Advanced Melanoma Treated with Vemurafenib

(2012) Jeffrey A. Sosman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

(2012) Suzanne L. Topalian et al.   NEW ENGLAND JOURNAL OF MEDICINE

EGFR Mutation Heterogeneity and the Mixed Response to EGFR Tyrosine Kinase Inhibitors of Lung Adenocarcinomas

(2012) Z.-Y. Chen et al.   ONCOLOGIST

A CD44high/EGFRlow Subpopulation within Head and Neck Cancer Cell Lines Shows an Epithelial-Mesenchymal Transition Phenotype and Resistance to Treatment

(2012) Linnea La Fleur et al.   PLoS One

Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1

(2012) K. Ohashi et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Noninvasive Identification and Monitoring of Cancer Mutations by Targeted Deep Sequencing of Plasma DNA

(2012) T. Forshew et al.   Science Translational Medicine

EGFR-Mediated Reactivation of MAPK Signaling Contributes to Insensitivity of BRAF -Mutant Colorectal Cancers to RAF Inhibition with Vemurafenib

(2012) Ryan B. Corcoran et al.   Cancer Discovery

Noncovalent Wild-type–Sparing Inhibitors of EGFR T790M

(2012) Ho-June Lee et al.   Cancer Discovery

Circumventing Cancer Drug Resistance in the Era of Personalized Medicine

(2012) Levi A. Garraway et al.   Cancer Discovery

HER2 Amplification: A Potential Mechanism of Acquired Resistance to EGFR Inhibition in EGFR -Mutant Lung Cancers That Lack the Second-Site EGFR T790M Mutation

(2012) Ken Takezawa et al.   Cancer Discovery

Ror1 Is a Pseudokinase That Is Crucial for Met-Driven Tumorigenesis

(2011) A. Gentile et al.   CANCER RESEARCH

EGFR Exon 19 Insertions: A New Family of Sensitizing EGFR Mutations in Lung Adenocarcinoma

(2011) M. He et al.   CLINICAL CANCER RESEARCH

Maintained Sensitivity to EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Lung Cancer Recurring after Adjuvant Erlotinib or Gefitinib

(2011) G. R. Oxnard et al.   CLINICAL CANCER RESEARCH

Phase I/II Trial of Cetuximab and Erlotinib in Patients with Lung Adenocarcinoma and Acquired Resistance to Erlotinib

(2011) Y. Y. Janjigian et al.   CLINICAL CANCER RESEARCH

Effectiveness of Tyrosine Kinase Inhibitors on "Uncommon" Epidermal Growth Factor Receptor Mutations of Unknown Clinical Significance in Non-Small Cell Lung Cancer

(2011) J.-Y. Wu et al.   CLINICAL CANCER RESEARCH

Disease Flare after Tyrosine Kinase Inhibitor Discontinuation in Patients with EGFR-Mutant Lung Cancer and Acquired Resistance to Erlotinib or Gefitinib: Implications for Clinical Trial Design

(2011) J. E. Chaft et al.   CLINICAL CANCER RESEARCH

Retreatment with erlotinib: Regain of TKI sensitivity following a drug holiday for patients with NSCLC who initially responded to EGFR-TKI treatment

(2011) A. Becker et al.   EUROPEAN JOURNAL OF CANCER

Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non–Small-Cell Lung Cancer in Asia (IPASS)

(2011) Masahiro Fukuoka et al.   JOURNAL OF CLINICAL ONCOLOGY

Randomized Phase II Study of Erlotinib Plus Tivantinib Versus Erlotinib Plus Placebo in Previously Treated Non–Small-Cell Lung Cancer

(2011) Lecia V. Sequist et al.   JOURNAL OF CLINICAL ONCOLOGY

Heterogeneous Distribution of EGFR Mutations Is Extremely Rare in Lung Adenocarcinoma

(2011) Yasushi Yatabe et al.   JOURNAL OF CLINICAL ONCOLOGY

Cetuximab Plus Irinotecan, Fluorouracil, and Leucovorin As First-Line Treatment for Metastatic Colorectal Cancer: Updated Analysis of Overall Survival According to Tumor KRAS and BRAF Mutation Status

(2011) Eric Van Cutsem et al.   JOURNAL OF CLINICAL ONCOLOGY

The Challenge and Promise of the Genomic Era

(2011) George W. Sledge   JOURNAL OF CLINICAL ONCOLOGY

Comparison of clinical outcome of patients with non-small-cell lung cancer harbouring epidermal growth factor receptor exon 19 or exon 21 mutations

(2011) Y.-W. Won et al.   JOURNAL OF CLINICAL PATHOLOGY

Comparison of KRAS and EGFR gene status between primary non-small cell lung cancer and local lymph node metastases: implications for clinical practice

(2011) Leina Sun et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

Phase II Trial of Dasatinib for Patients with Acquired Resistance to Treatment with the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Erlotinib or Gefitinib

(2011) Melissa L. Johnson et al.   Journal of Thoracic Oncology

Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trial

(2011) Roy S Herbst et al.   LANCET

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study

(2011) Caicun Zhou et al.   LANCET ONCOLOGY

Conversion from the “oncogene addiction” to “drug addiction” by intensive inhibition of the EGFR and MET in lung cancer with activating EGFR mutation

(2011) Kenichi Suda et al.   LUNG CANCER

Liposomal Delivery of MicroRNA-7-Expressing Plasmid Overcomes Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor-Resistance in Lung Cancer Cells

(2011) K. Rai et al.   MOLECULAR CANCER THERAPEUTICS

Drug development to overcome resistance to EGFR inhibitors in lung and colorectal cancer

(2011) Rodrigo Dienstmann et al.   Molecular Oncology

FAS and NF-κB signalling modulate dependence of lung cancers on mutant EGFR

(2011) Trever G. Bivona et al.   NATURE

EGFR and MET receptor tyrosine kinase–altered microRNA expression induces tumorigenesis and gefitinib resistance in lung cancers

(2011) Michela Garofalo et al.   NATURE MEDICINE

Drug-Induced Effects on Erlotinib Metabolism

(2011) Olivier Mir et al.   NEW ENGLAND JOURNAL OF MEDICINE

Treatment of Non–Small-Cell Lung Cancer with Erlotinib or Gefitinib

(2011) Vince D. Cataldo et al.   NEW ENGLAND JOURNAL OF MEDICINE

The Role of Irreversible HER Family Inhibition in the Treatment of Patients with Non-Small Cell Lung Cancer

(2011) E. Kwak   ONCOLOGIST

Epithelial–mesenchymal-transition induced by EGFR activation interferes with cell migration and response to irradiation and cetuximab in head and neck cancer cells

(2011) Carmen Holz et al.   RADIOTHERAPY AND ONCOLOGY

Activation of ERBB2 Signaling Causes Resistance to the EGFR-Directed Therapeutic Antibody Cetuximab

(2011) K. Yonesaka et al.   Science Translational Medicine

Differential Inhibitor Sensitivity of Anaplastic Lymphoma Kinase Variants Found in Neuroblastoma

(2011) S. C. Bresler et al.   Science Translational Medicine

Optimization of Dosing for EGFR-Mutant Non-Small Cell Lung Cancer with Evolutionary Cancer Modeling

(2011) J. Chmielecki et al.   Science Translational Medicine

Amplification of CRKL Induces Transformation and Epidermal Growth Factor Receptor Inhibitor Resistance in Human Non-Small Cell Lung Cancers

(2011) H. W. Cheung et al.   Cancer Discovery

The BATTLE Trial: Personalizing Therapy for Lung Cancer

(2011) Edward S. Kim et al.   Cancer Discovery

A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations

(2010) Sreenath V. Sharma et al.   CELL

Highly Active Antitumor Therapy (HAATT) for Epidermal Growth Factor Receptor-Mutant Lung Cancer

(2010) J. Chmielecki et al.   CLINICAL CANCER RESEARCH

HGF Rescues Colorectal Cancer Cells from EGFR Inhibition via MET Activation

(2010) D. Liska et al.   CLINICAL CANCER RESEARCH

Reciprocal and Complementary Role of MET Amplification and EGFR T790M Mutation in Acquired Resistance to Kinase Inhibitors in Lung Cancer

(2010) K. Suda et al.   CLINICAL CANCER RESEARCH

Small-Cell Carcinoma With an Epidermal Growth Factor Receptor Mutation in a Never-Smoker With Gefitinib-Responsive Adenocarcinoma of the Lung

(2010) Naheed Alam et al.   Clinical Lung Cancer

Cetuximab and First-Line Taxane/Carboplatin Chemotherapy in Advanced Non–Small-Cell Lung Cancer: Results of the Randomized Multicenter Phase III Trial BMS099

(2010) Thomas J. Lynch et al.   JOURNAL OF CLINICAL ONCOLOGY

Randomized Phase III Study of Panitumumab With Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) Compared With FOLFIRI Alone As Second-Line Treatment in Patients With Metastatic Colorectal Cancer

(2010) Marc Peeters et al.   JOURNAL OF CLINICAL ONCOLOGY

Randomized, Phase III Trial of Panitumumab With Infusional Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX4) Versus FOLFOX4 Alone As First-Line Treatment in Patients With Previously Untreated Metastatic Colorectal Cancer: The PRIME Study

(2010) Jean-Yves Douillard et al.   JOURNAL OF CLINICAL ONCOLOGY

A Randomized Phase 2 Study of Erlotinib Alone and in Combination with Bortezomib in Previously Treated Advanced Non-small Cell Lung Cancer

(2010) Thomas J. Lynch et al.   Journal of Thoracic Oncology

Discordance of Molecular Biomarkers Associated with Epidermal Growth Factor Receptor Pathway between Primary Tumors and Lymph Node Metastasis in Non-small Cell Lung Cancer

(2010) Sarah Park et al.   Journal of Thoracic Oncology

Cancer-Associated Fibroblasts Derived from EGFR-TKI-Resistant Tumors Reverse EGFR Pathway Inhibition by EGFR-TKIs

(2010) S. R. Mink et al.   MOLECULAR CANCER RESEARCH

Understanding resistance to EGFR inhibitors—impact on future treatment strategies

(2010) Deric L. Wheeler et al.   Nature Reviews Clinical Oncology

Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR

(2010) Makoto Maemondo et al.   NEW ENGLAND JOURNAL OF MEDICINE

EML4-ALK Mutations in Lung Cancer That Confer Resistance to ALK Inhibitors

(2010) Young Lim Choi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer

(2010) Eunice L. Kwak et al.   NEW ENGLAND JOURNAL OF MEDICINE

Amplification of EGFR T790M causes resistance to an irreversible EGFR inhibitor

(2010) D Ercan et al.   ONCOGENE

Rapidly Acquired Resistance to EGFR Tyrosine Kinase Inhibitors in NSCLC Cell Lines through De-Repression of FGFR2 and FGFR3 Expression

(2010) Kathryn E. Ware et al.   PLoS One

TGF-  IL-6 axis mediates selective and adaptive mechanisms of resistance to molecular targeted therapy in lung cancer

(2010) Z. Yao et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

PIK3CA Mutations in Colorectal Cancer Are Associated with Clinical Resistance to EGFR-Targeted Monoclonal Antibodies

(2009) A. Sartore-Bianchi et al.   CANCER RESEARCH

PTEN Loss Contributes to Erlotinib Resistance in EGFR-Mutant Lung Cancer by Activation of Akt and EGFR

(2009) M. L. Sos et al.   CANCER RESEARCH

Immunotherapy of Malignant Disease with Tumor Antigen-Specific Monoclonal Antibodies

(2009) M. Campoli et al.   CLINICAL CANCER RESEARCH

Impact of Epidermal Growth Factor Receptor and KRAS Mutations on Clinical Outcomes in Previously Untreated Non-Small Cell Lung Cancer Patients: Results of an Online Tumor Registry of Clinical Trials

(2009) D. M. Jackman et al.   CLINICAL CANCER RESEARCH

Combined Vascular Endothelial Growth Factor Receptor and Epidermal Growth Factor Receptor (EGFR) Blockade Inhibits Tumor Growth in Xenograft Models of EGFR Inhibitor Resistance

(2009) G. N. Naumov et al.   CLINICAL CANCER RESEARCH

Noninvasive Detection of EGFR T790M in Gefitinib or Erlotinib Resistant Non-Small Cell Lung Cancer

(2009) Y. Kuang et al.   CLINICAL CANCER RESEARCH

Epidermal growth factor receptor in relation to tumor development: EGFR gene and cancer

(2009) Tetsuya Mitsudomi et al.   FEBS Journal

Analysis of PTEN, BRAF, and EGFR Status in Determining Benefit From Cetuximab Therapy in Wild-Type KRAS Metastatic Colon Cancer

(2009) Pierre Laurent-Puig et al.   JOURNAL OF CLINICAL ONCOLOGY

Adjuvant Chemotherapy for Non–Small-Cell Lung Cancer: It Does Not Always Fade With Time

(2009) Jean-Yves Douillard   JOURNAL OF CLINICAL ONCOLOGY

Clinical Definition of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small-Cell Lung Cancer

(2009) David Jackman et al.   JOURNAL OF CLINICAL ONCOLOGY

Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial

(2009) Robert Pirker et al.   LANCET

Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial

(2009) Tetsuya Mitsudomi et al.   LANCET ONCOLOGY

Novel mutant-selective EGFR kinase inhibitors against EGFR T790M

(2009) Wenjun Zhou et al.   NATURE

Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma

(2009) Tony S. Mok et al.   NEW ENGLAND JOURNAL OF MEDICINE

Multi-Determinants Analysis of Molecular Alterations for Predicting Clinical Benefit to EGFR-Targeted Monoclonal Antibodies in Colorectal Cancer

(2009) Andrea Sartore-Bianchi et al.   PLoS One

Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study

(2008) R. A. Larson et al.   BLOOD

Intratumor heterogeneity of epidermal growth factor receptor mutations in lung cancer and its correlation to the response to gefitinib

(2008) Kazuya Taniguchi et al.   CANCER SCIENCE

Long-Term Results From a Randomized Phase II Trial of Standard- Versus Higher-Dose Imatinib Mesylate for Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing KIT

(2008) Charles D. Blanke et al.   JOURNAL OF CLINICAL ONCOLOGY

Wild-TypeKRASIs Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer

(2008) Rafael G. Amado et al.   JOURNAL OF CLINICAL ONCOLOGY

Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer

(2008) Helena Linardou et al.   LANCET ONCOLOGY

The T790M "gatekeeper" mutation in EGFR mediates resistance to low concentrations of an irreversible EGFR inhibitor

(2008) N. Godin-Heymann et al.   MOLECULAR CANCER THERAPEUTICS

EGFR Antagonists in Cancer Treatment

(2008) Fortunato Ciardiello et al.   NEW ENGLAND JOURNAL OF MEDICINE

Detection of Mutations inEGFRin Circulating Lung-Cancer Cells

(2008) Shyamala Maheswaran et al.   NEW ENGLAND JOURNAL OF MEDICINE

K-rasMutations and Benefit from Cetuximab in Advanced Colorectal Cancer

(2008) Christos S. Karapetis et al.   NEW ENGLAND JOURNAL OF MEDICINE

Platinum-Based Chemotherapy plus Cetuximab in Head and Neck Cancer

(2008) Jan B. Vermorken et al.   NEW ENGLAND JOURNAL OF MEDICINE

Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members

(2008) D L Wheeler et al.   ONCOGENE

The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP

(2008) C.-H. Yun et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA